Chandigarh, Oct. 9 -- The Haryana Food and Drugs Administration (FDA) have issued show cause notices to four pharmaceutical companies for misbranding cough-cold syrups containing phenylephrine hydrochloride and chlorpheniramine maleate, thus contravening provisions of Drugs and Cosmetics Act.

While the Union health ministry had in April 2025 restricted the manufacture, sale or distribution of all formulations of fixed dose combination (FDC) of chlorpheniramine maleate and phenylephrine hydrochloride subject to condition that the manufacturers will mention the warning "fixed dose combination shall not be used in children below four years of age" on the label and package insert or the promotional literature of the drug, the cough cold syru...